1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Rina Plattner: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
Melanoma (1)
binimetinib (1) · dabrafenib (1) · encorafenib (1) · nilotinib (1) · trametinib (1)
United States (1)
Ruta Arays, MD (1)
R01CA258751 (1)